Trial reportBritish journal of cancer2012
Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study.
Trial report in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00297258 (Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of GW786034 in Patients With Relapsed or Refractory Soft Tissue Sarcoma
Who cites it
27 citing papers in PubMed, 49 citations in OpenAlex.
- Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata.British journal of cancer · 2023Trial
- Trial
- Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Trial
- Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.Targeted oncology · 2014Trial
- Electrochemotherapy treatment of locally advanced and metastatic soft tissue sarcomas: results of a non-comparative phase II study.World journal of surgery · 2014Trial
- Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Trial
- Comprehensive Molecular Characterization of Soft Tissue Sarcoma for Prediction of Pazopanib-Based Treatment Response.Cancer research and treatment · 2023Article
- Regorafenib for the Treatment of Sarcoma.Current treatment options in oncology · 2022Review
- Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy.Cancers · 2021Review
- Primary vulvar leiomyosarcoma localized in the Bartholin's gland area: A case report and review.Molecular and clinical oncology · 2021Article
- PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma.BMC cancer · 2021Article
- Pharmacogenomics Biomarkers of Soft Tissue Sarcoma Therapies.Frontiers in oncology · 2020Review
- Sarcoma Tumor Microenvironment.Advances in experimental medicine and biology · 2020Article
- Anti-Angiogenic Agents in Management of Sarcoma Patients: Overview of Published Trials.Frontiers in oncology · 2020Review
- Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours.Nature reviews. Clinical oncology · 2018Review
- Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib.The Korean journal of internal medicine · 2018Article
- Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing.Clinical pharmacokinetics · 2017Review
- Article
- Targeted therapy for soft tissue sarcomas in adolescents and young adults.Adolescent health, medicine and therapeutics · 2017Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPazopanib has activity in relapsed non-adipocytic soft-tissue sarcomas (STS). A series of serum cytokines and angiogenic factors (CAFs) at baseline and changes in soluble vascular endothelial growth factor receptor-2 (sVEGFR2) or placental-derived growth factor (PlGF) levels during treatment were explored for their association with outcome.
methodsTwenty-three baseline CAFs, and sVEGFR2 and PlGF changes were measured in 85 and 32 patients, respectively. Associations between baseline CAF levels and efficacy parameters, plus between-week 12 sVEGFR2 and PlGF levels and pazopanib-specific toxicities were investigated.
resultsAt baseline, low interleukin (IL)-12 p40 subunit and MPC3 levels were associated with better progression-free survival (PFS) at 12 weeks (PFS(12wks)), low basic nerve growth factor and hepatocyte growth factor with a better PFS, and low inter-cellular adhesion molecule-1 and IL-2 receptor alpha with prolonged overall survival (OS; all P<0.05). Pazopanib decreased sVEGFR2 and increased PlGF levels. Low sVEGFR2 and high PlGF levels at week 12 were associated with higher-grade hypertension, with TSH elevations and with poorer PFS(12wks), and OS (both P<0.05).
conclusionSeveral baseline CAFs were related to outcome parameters. Low sVEGFR2 and high PlGF at week 12 associate with several pazopanib-specific toxicities and poorer efficacy. If confirmed, these factors may be used as early markers for response to and toxicity from pazopanib, enabling further individualisation of STS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.